Latest Intelligence in Europe

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: Torisel valuable for poor-risk patients

The European Commission has granted regulatory approval to Wyeth's Torisel, making it the first mTOR kinase inhibitor to reach the EU market. While renal cell carcinoma patients are becoming increasingly well served in terms of treatment options, Torisel represents a valuable addition for poor-risk patients, who traditionally have been the most difficult to treat.

Published By Datamonitor
27 Nov 2007
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Wyeth: a question of consolidation

Revenues at Wyeth have climbed despite declining sales of key products such as Premarin and Prevnar. Litigation expenses continue to impact the bottom line, but a cash injection resulting from the merger of Immunex and Amgen has improved the company's financial situation. There are signs the company could be ripe for consolidation once more.

Published By Datamonitor
30 Jan 2003
Expert View
Expert View

Wunelli and SSP bet on the mass market

In the burgeoning telematics space Wunelli and SSP have partnered to launch a smartphone-based product targeting the mass market. The simplicity of such a solution will appeal to consumers, but data quality issues could limit the benefits to insurers.

Published By Datamonitor
14 May 2013
CommentWire
CommentWire

WSA: the friendlier face of alcohol regulation

In response to a government interim report on alcohol harm reduction, the WSA has released its own recommendations. Unsurprisingly, it argues against the more drastic actions the government proposes. However, the WSA's less costly suggestions are nothing new. They require little effort on the part of the industry and it is likely that they will also have little effect.

Published By Datamonitor
15 Dec 2003
CommentWire
CommentWire

Wrigley: the innovation game

Wrigley's new oral health gum offering shows it understands well the need to stay at the cutting edge of product innovation. With a consumer base hungry for these products, Wrigley must use its brand strength to fight off competitors that are keen for a share of this lucrative market.<BR />

Published By Datamonitor
08 Aug 2003
CommentWire
CommentWire

Wrigley: introducing itself to the chocolate market

The purchase of an 80% stake in premium chocolate company A. Korkunov will allow Wrigley, which already operates in Russia, to form effective synergies with the company, through leveraging existing distribution networks, and enable it to capitalize on the growing disposable income of the country's burgeoning middle class. The move will also allow it to branch out into chocolate confectionery.

Published By Datamonitor
24 Jan 2007
CommentWire
CommentWire

Wrigley: has the bubble burst?

US chewing gum giant Wm Wrigley has accused Cadbury Schweppes of breaching UK competition laws in the launch of its Trident gum, and is considering legal action, according to The Sunday Telegraph. Furthermore, Wrigley's UK market share has fallen since the launch of Trident, and if the company fails to address other underlying reasons for its diminishing share, this is likely to drop further.

Published By Datamonitor
28 Mar 2007

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.